Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

ASH 2018: Phoenix and other DLBCL study updates

Written by | 5 Feb 2019

Professor Anas Younes (New York, USA) and Dr Andrew Davies (Southampton, UK) discuss the outcomes from the Pheonix study, with Professor Anas Younes (New York, USA) highlighting future… read more.

ASH 2018: Advances in RRMM

Written by | 25 Jan 2019

Relapsed and refractory MM continues to challenge clinicians and several oral abstracts at ASH 2018 presented new and updated data on delaying disease progression and prolonging survival after… read more.

ASH 2018: TOURMALINE-MM3 study

Written by | 25 Jan 2019

Article written by Maria Dalby. Interview by Hannah Chatfield. Professor Kwee Yong (London, UK), Dr Martin Kaiser (London, UK) and Professor Gareth Morgan (Arkansas, USA) discuss the results from the Tourmaline-MM3 study and… read more.

ASH 2018: Novel agents in combination for relapsed/refractory Hodgkin’s lymphoma: the ECOG-ACRIN E4412 study

Written by | 14 Jan 2019

Article written by Maria Dalby. Interviews by Hannah Chatfield. Immune checkpoints such as CTLA-4 and PD-1 are known to play a vital part in anti-tumour T-cell function in… read more.

ASH 2018: Hodgkin lymphoma: beyond ABVD for everyone

Written by | 14 Jan 2019

Article by Maria Dalby. Interviews by Hannah Chatfield Achieving the ultimate goals of maintaining cure and minimising long-term toxicity in Hodgkin lymphoma (HL) requires individualised therapy based on… read more.

UEGW 2018: Future therapies in IBD

Written by | 3 Nov 2018

Professor Stefan Schreiber (Germany) discusses  the future of therapies in IBD.

BSH 2018: Hodgkin lymphoma: tackling treatment challenges in the older patient

Written by | 21 Jun 2018

Managing Hodgkin lymphoma in elderly patients can be challenging, given that trial data do not reflect the picture in elderly patients and performance status can vary widely. The… read more.

BSH 2018: Molecular biology to drive rational drug usage

Written by | 20 Jun 2018

Gene expression profiling has shown that that the activated B-cell and germinal centre B-cell subtypes of diffuse large B-cell lymphoma are driven by different oncogenic pathways and this may… read more.

BSH 2018 Highlights

Written by | 20 Jun 2018

In the video, Dr Cathy Burton (Leeds), Dr Stella Bowcock (London) and Dr Stephen Robinson (Bristol) give their highlights from this year’s BSH meeting, including the Lymphoma Specialist Interest Group (SIG) which held a… read more.

Updated findings from the German Hodgkin Study Group HD18 trial

Written by | 20 Jun 2018

BEACOPP treatment offers considerable advantages in terms of overall survival and low dose regimens offer short, safe and effective treatment for newly-diagnosed advanced-stage HL patients …… 

BSH 2018: Creating off-site, nurse-led treatment units for administration of chemotherapy to people with lymphoma

Written by | 20 Jun 2018

The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.

BSH 2018: Debate: CAR-T cell therapy will become the standard of care for relapsed high-grade B-cell lymphoma within 5 years

Written by | 11 May 2018

Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.